author-photo

Jeanne Connor

University of Alabama at Birmingham

3

Papers

17

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (14)
A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL).

2005 Blood
Show All
- Source
- Cite
- Save
Citations (0)